Ganaxolone Expanded Access Program Compassionate Use

Summary

The primary objective is to provide GNX to patients ≥ 2 years with CDD-related seizures who are refractory to, or intolerant of, standard therapy.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications